



# The Henry Schueler 41 & 9 Foundation Second International Forum on Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection

## AGENDA

**Dates:** November 7<sup>th</sup> and 8<sup>th</sup>, 2019

**Location:** Palmer House, 17 East Monroe Street, Chicago, Illinois 60603

### Co-Chairs:

**Thomas J. Walsh, MD, PhD (hon), FIDSA, FAAM, FCCP, FECMM, FAAAS**

Founding Director, Transplantation-Oncology Infectious Diseases Program Chief,  
Infectious Diseases Translational Research Laboratory

Professor of Medicine, Pediatrics, and Microbiology & Immunology

Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital Henry  
Schueler 41 & 9 Foundation Scholar in Mucormycosis

Adjunct Professor of Pathology, The Johns Hopkins University School of Medicine Adjunct  
Professor of Medicine, University of Maryland School of Medicine

**Dimitrios P. Kontoyiannis, MD, ScD, PhD (Hon), FACP, FIDSA, FECMM, FAAM, FAAAS**

Texas 4000 Distinguished Endowed Professor For Cancer Research

Deputy Head, Division of Internal Medicine

The University of Texas MD Anderson Cancer Center

Adjunct Professor Baylor College of Medicine Adjunct

Professor University of Houston

### Objectives:

1. To review the advances in understanding of the epidemiology, genomics, pathogenesis, and host defenses of the Mucorales and mucormycosis
2. To discuss the advances made in diagnosis and treatment of mucormycosis
3. To develop new objectives for improving the outcome of patients with mucormycosis
4. To formulate a path for an updated publication supplement to the 2012 publication of [Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis](#) (Clin Infect Dis. 54 Suppl 1:S1-4; 2012)



# The Henry Schueler 41 & 9 Foundation Second International Forum on Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection

## AGENDA

**Day 1: Thursday, November 7, 2019**

### **Epidemiology of Mucormycosis: Lessons Learned During the Past 5 Years**

**8:30 a.m. – Welcome & Origins, Mission, & Achievements of The Henry Schueler 41 & 9 Foundation**  
*Speaker: Matthew Schueler, Henry Schueler 41 & 9 Foundation*

**8:45 a.m. – Introduction to the Second Henry Schueler 41 & 9 Foundation Forum for Mucormycosis & Objectives**  
*Speaker: Thomas J. Walsh, Weill Cornell Medicine, New York, NY, USA*

**9:00 a.m. – Speaker Representative from Astellas**

**9:15 a.m. – Speaker Representative from Lediant**

**9:30 a.m. – History of Mucormycosis**

*Speaker: Anna Skiada, Laiko Hospital, National and Kapodistrian University of Athens, First Department of Medicine, Athens, Greece*

**10:00 a.m. - Who is at Risk for Infection and What are the Outcomes?**

*Speaker: Olivier Lortholary, Institute Pasteur, Paris, France*

**10:30 a.m. - Trauma-related Mucormycosis: The Winds of War and Their Mycological Consequences**

*Speaker: Duane Hospenthal, University of Texas San Antonio, San Antonio, Texas, USA*

**11:00 a.m. – 15 Minute Break** (*snacks & refreshments provided to general attendees*)

**11:15 a.m. – Hospital Acquired Mucormycosis: In Search of the Environmental Sources of Infection**

*Speaker: M. Hong Nguyen, University of Pittsburgh, Pittsburgh, PA, USA*

**11:45 a.m. – Epidemiology of Pediatric Mucormycosis: Small Patients with Great Challenges**

*Speaker: Emmanouel Roilides, Aristotle University, Thessaloniki, Greece*

**12:15 p.m. – Roundtable on Epidemiology of Mucormycosis**

**12:45 p.m. – Lunch Break** (*lunch not provided to general attendees*)

### **Pathogenesis and Host Defense**

**2:00 p.m. – Advances in Understanding the Pathogenesis of Mucormycosis**

*Speaker: Ashraf Ibrahim, UCLA, Los Angeles, CA, USA*



# The Henry Schueler 41 & 9 Foundation Second International Forum on Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection

## AGENDA

**2:30 p.m. – Insights into Pathogenesis of Mucormycosis from Mini-host Models**

*Speaker: Dimitrios Kontoyiannis, MDACC, Houston, TX, USA*

**3:00 p.m. – Innate Host Defenses against Mucorales**

*Speaker: George Chamilos, University of Crete, Crete, Greece*

**3:30 p.m. – 15 Minute Break** (*snacks & refreshments provided to general attendees*)

**3:45 p.m. – Genomics in Mucorales Species**

*Speaker: Vincent Bruno, University of Maryland, Baltimore, MD, USA*

**4:15 p.m. – Roundtable on Pathogenesis of Mucormycosis**

**4:45 p.m. – Summary for the day**

*Speaker: Dimitrios Kontoyiannis, MDACC, Houston, TX, USA*

**6:00 p.m. – Speaker Dinner** (*by invite only*)

## Day 2: Friday, November 8, 2019

### Clinical and Laboratory Diagnosis: Pathways to Early Recognition, Preemptive Intervention, and Improved Outcome

**8:00 a.m. – Assessment of Mucormycosis in Adult Patients**

*Speaker: Olivier Lortholary, Institute Pasteur, Paris, France*

**8:30 a.m. – Assessment of Mucormycosis in Pediatric Patients**

*Speaker: Emmanuel Roilides, Aristotle University, Thessaloniki, Greece*

**9:00 a.m. – Clinical Laboratory Diagnosis of Mucormycosis: What are the Standards and How Can They be Improved**

*Speaker: Sean Zhang, Johns Hopkins University School of Medicine, Baltimore, MD*

**9:30 a.m. – From Pathogenesis to Molecular Diagnosis of Mucormycosis**

*Speaker: Ashraf Ibrahim, UCLA, Los Angeles, CA, USA*

**10:00 a.m. – 15 Minute Break** (*snacks & refreshments provided to general attendees*)

**10:15 a.m. – Developing laboratory diagnostic tools: bring advances from bench to bedside**

*Speaker: Thomas J. Walsh, Weill Cornell Medicine, New York, NY USA*

**10:45 a.m. – Roundtable Discussion on Diagnosis of Mucormycosis**



# The Henry Schueler 41 & 9 Foundation Second International Forum on Mucormycosis: Meeting the Evolving Challenges of a Lethal Infection

## AGENDA

**11:45 a.m. – Lunch Break** (*lunch not provided to general attendees*)

### Treatment and Outcome

**12:45 p.m. – Antifungal Pharmacology and Treatment of Mucormycosis**

*Speaker: Russel Lewis, University of Bologna, Bologna, Italy*

**1:15 p.m. – Liposomal Amphotericin B for Treatment of Mucormycosis**

*Speaker: Thomas J. Walsh, Weill Cornell Medicine, New York, New York, USA*

**1:45 p.m. – Amphotericin B Lipid Complex for Treatment of Mucormycosis**

*Speaker: Thomas J. Walsh, Weill Cornell Medicine, New York, New York, USA*

**2:15 p.m. – 15 Minute Break** (*snacks & refreshments provided to general attendees*)

**2:30 p.m. – Isavuconazole for Treatment of Mucormycosis**

*Speaker: Kate Mullane, University of Chicago, Chicago, IL, USA*

**3:00 p.m. – Investigational Agents for Treatment of Mucormycosis**

*Speaker: Matthew McCarthy, Weill Cornell Medicine, New York, NY, USA*

**3:30 p.m. – Combination Antifungal Therapy for Treatment of Mucormycosis**

*Speaker: Dimitrios P. Kontoyiannis, MDACC, Houston, TX, USA*

**4:00 p.m. – Adjunctive Therapeutic Modalities: Immune Augmentation and Hyperbaric Oxygen for Treatment of Mucormycosis**

*Speaker: Emmanuel Roilides, Aristotle University and Hippokraton Hospital, Thessaloniki, Greece*

**4:30 p.m. – Roundtable on Treatment of Mucormycosis**

**5:15 p.m. – Future Directions**

*Speaker: Dimitrios P. Kontoyiannis, MDACC, Houston, TX, USA*

**5:30 p.m. – CID Monograph on Mucormycosis**

*Speaker: Thomas J. Walsh, Weill Cornell Medicine, New York, New York, USA*

**5:45 p.m. – Final Reflections and Closing**

*Speaker: Matthew Schueler, Henry Schueler 41 & 9 Foundation*